Is medical Tourism rising in America? 

What the numbers reveal about world-class cancer care

When it comes to fighting cancer, outcomes speak louder than words. And one of the clearest ways to measure success? Five-year relative survival rates — essentially, the percentage of patients still with us five years after diagnosis, compared to the general population.

It's not a perfect metric (more on that later), but it's a powerful one. So how do two healthcare heavyweights — the United States and South Korea — stack up? Let's dive into the data.

The Headline Numbers

South Korea's Performance

South Korea has achieved a five-year relative survival rate of approximately 72.9% for all cancers combined, based on diagnoses from 2018-2022. Breaking it down by gender, the 2017-2021 period showed about 72.1% survival for both sexes — 66.1% for men and 78.2% for women.

But here's where it gets really interesting. For specific cancer types, Korea is crushing it:

• Thyroid cancer: ~100.1% survival (yes, you read that right — more on this below)
• Breast cancer: ~93.8% survival
• Stomach cancer: ~77.9% survival
• Colon cancer: ~74.3% survival
• Liver cancer: ~39.3% survival

The United States' Track Record

As of 2025, nearly 18.6 million Americans are living with a history of cancer — a testament to improving treatments. Survival rates have climbed dramatically, from about 49% for diagnoses made in 1975-77 to roughly 70% for those diagnosed in 2015-21.

For the specific cancers mentioned above, US comparison points include:

• Thyroid cancer: ~98.4% survival
• Stomach cancer: ~36.4% survival
• Colon cancer: ~65.0% survival
• Liver cancer: ~21.7% survival

What Jumps Out?

Let's be clear: both countries deliver world-class cancer care. But some patterns are impossible to ignore:

Korea's Edge in Digestive Cancers

The gap in stomach cancer survival is striking: 77.9% in Korea versus 36.4% in the US. Similarly, liver cancer survival is 39.3% in Korea compared to 21.7% in the US.

Why? Partly because stomach cancer is far more common in Korea, driving specialized expertise and aggressive screening programs. When you see something more often, you get better at treating it.

Neck-and-Neck on High-Survival Cancers

For cancers where both countries already excel — thyroid, breast, prostate — the numbers are excellent across the board. Korea edges slightly ahead in some datasets, but both nations are delivering remarkable outcomes.

The Big Picture

Korea's overall figure of approximately 72.9% for all cancers is competitive and appears at or above the historical US benchmark of around 70%. Translation? Korea isn't just keeping pace — it's setting the pace in several key areas.

So What's Korea's Secret?

Several factors appear to be working in Korea's favor:

1. Early Detection Culture

Korea's national cancer screening systems have expanded and improved, helping detect cancers at more treatable, early stages. Catching cancer early is half the battle.

2. Infrastructure Investment

From cutting-edge imaging to robotic surgery systems, Korea has invested heavily in medical technology and hospital infrastructure — creating centers of excellence that rival anywhere in the world.

3. Centralized Strategy

Korea's centralized registries, monitoring, and control programs may contribute to consistently improved outcomes and favorable mortality-to-incidence ratios. When you track everything, you can improve everything.

4. The Specialization Effect

High-volume centers develop deep expertise. Korean hospitals treating hundreds of stomach or liver cancer cases annually accumulate knowledge that translates directly into better outcomes.

The Fine Print (Important!)

Before you book a flight based on statistics alone, let's add some context:

Survival Isn't the Whole Story

A five-year survival rate means people are alive five years later — it doesn't guarantee long-term cure or quality of life. Treatment side effects, functional outcomes, and long-term health all matter.

Lead Time Bias Is Real

If a country detects cancers earlier, survival statistics will improve due to potential "lead time bias". Finding cancer sooner makes it look like people live longer, even if the actual course of disease hasn't changed.

Data Isn't Always Apples-to-Apples

Datasets differ in methodology, years covered, populations, and how "relative survival" is calculated. Direct comparisons require caution.

Your Mileage Will Vary

Cancer type, stage, patient health, treatment center, and other variables drive outcomes — national averages are useful for policy comparison but not predictive for an individual.

One More Thing

For aggressive cancers, certain countries including both the US and Korea still face very poor survival rates despite overall improvements. Pancreatic cancer, for example, remains brutally difficult regardless of where you're treated.

The Bottom Line

The data paints a compelling picture: South Korea's approximately 72.9% five-year survival rate for all cancers is highly competitive, and for several major cancers including stomach, liver, and colorectal, Korea appears to outperform US benchmarks.

Does this mean everyone should hop on a plane to Seoul? Not necessarily. Treatment decisions should consider specific cancer type, stage at diagnosis, treatment center quality, patient health, and logistical/financial factors.

But if you're exploring options for cancer care — especially for digestive cancers where Korea particularly excels — the statistics suggest you'd be in extraordinarily capable hands.

Because at the end of the day, what matters most isn't which country "wins" the cancer survival contest. It's that patients have access to the world-class care that gives them the best possible chance.

And on that measure? Both nations are delivering.